Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2020 Jun 1;6(6):927-929.
doi: 10.1001/jamaoncol.2020.0571.

Central Nervous System as Possible Site of Relapse in ERBB2-Positive Metastatic Colorectal Cancer: Long-term Results of Treatment With Trastuzumab and Lapatinib

Andrea Sartore-Bianchi  1   2 , Sara Lonardi  3 , Massimo Aglietta  4   5 , Cosimo Martino  4 , Fortunato Ciardiello  6 , Silvia Marsoni  7 , Salvatore Siena  1   2
Affiliations
Clinical Trial

Central Nervous System as Possible Site of Relapse in ERBB2-Positive Metastatic Colorectal Cancer: Long-term Results of Treatment With Trastuzumab and Lapatinib

Andrea Sartore-Bianchi et al. JAMA Oncol. .

Abstract

This secondary analysis of data from the HERACLES-A clinical trial examines long-term outcomes in 32 patients with colorectal cancer treated with trastuzumab and lapatinib.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Sartore-Bianchi is consultant/advisory member for Amgen, Bayer, Sanofi, and Servier; Dr Lonardi reports consulting or advisory roles in Amgen, Bayer, Merck, Lilly, and Servier; speakers' bureau roles at Lilly, Roche, and BMS, and research funding from Amgen, and Merck; Dr Ciardiello reported recepit of honoraria or consultation fees for speaker, consultancy, or advisory roles at Amgen, Bayer, Bristol-Myers Squibb, Celgene, Merck Serono, Pfizer, Roche, Servier; direct research funding as the principal investigator for institutional research projects from Amgen, Bayer, Merck Serono, Roche, Ipsen; institutional financial interests, financial support for clinical trials, or contracted research from Merck Serono, Roche, Symphogen, Array; leadership Positions in Professional Societies (non-financial interests) including ESMO past president, and president of the Associazione Italiana Oncologia Toracica; Dr Siena is advisory board member for Amgen, Bayer, BMS, Celgene, Incyte, Merck, Novartis, Roche, Seattle Genetics.

References

    1. Siena S, Sartore-Bianchi A, Marsoni S, et al. . Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer. Ann Oncol. 2018;29(5):1108-1119. doi:10.1093/annonc/mdy100 - DOI - PMC - PubMed
    1. Sartore-Bianchi A, Trusolino L, Martino C, et al. . Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016;17(6):738-746. doi:10.1016/S1470-2045(16)00150-9 - DOI - PubMed
    1. Bertotti A, Migliardi G, Galimi F, et al. . A molecularly annotated platform of patient-derived xenografts (“xenopatients”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov. 2011;1(6):508-523. doi:10.1158/2159-8290.CD-11-0109 - DOI - PubMed
    1. Siravegna G, Sartore-Bianchi A, Nagy RJ, et al. . Plasma HER2 (ERBB2) copy number predicts response to HER2-targeted therapy in metastatic colorectal cancer. Clin Cancer Res. 2019. doi:10.1158/1078-0432.CCR-18-3389 - DOI - PubMed
    1. Siravegna G, Lazzari L, Crisafulli G, et al. . Radiologic and genomic evolution of individual metastases during HER2 blockade in colorectal cancer. Cancer Cell. 2018;34(1):148-162.e7. doi:10.1016/j.ccell.2018.06.004 - DOI - PubMed

MeSH terms